NewAmsterdam Pharma (NAMS) Free Cash Flow (2023 - 2026)
NewAmsterdam Pharma (NAMS) reported Free Cash Flow of -$30.6 million for Q1 2026, up 16.01% on a YoY basis from -$26.4 million in Q1 2025, and up 25.22% sequentially from -$41.0 million in Q4 2025.
NewAmsterdam Pharma (NAMS) Free Cash Flow (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma (NAMS) has 4 years of Free Cash Flow data on file, last reported at -$30.6 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 16.01% year-over-year to -$30.6 million; the trailing twelve-month figure through Mar 2026 stood at -$142.2 million (down 1.03% YoY), and the FY2025 full-year result was -$148.0 million, up 7.04% from the prior year.
- Free Cash Flow advanced to -$30.6 million in Q1 2026, from -$41.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$12.6 million in Q3 2024 to a low of -$55.0 million in Q1 2024.
- A 4-year average of -$37.5 million and a median of -$37.0 million in 2024 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow jumped 73.23% in 2024 and tumbled 160.88% in 2025, its largest moves.
- Tracing NAMS's Free Cash Flow over 4 years: stood at -$33.1 million in 2023, then retreated by 13.32% to -$37.5 million in 2024, then declined by 9.31% to -$41.0 million in 2025, then increased by 25.22% to -$30.6 million in 2026.
- Business Quant data shows NAMS's Free Cash Flow at -$30.6 million in Q1 2026, -$41.0 million in Q4 2025, and -$32.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | NewAmsterdam Pharma | 3.72 Bn | 3.72 Bn | - | -30.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.64 Mn |
| Mar 31, 2026 | -30.64 Mn |
| Dec 31, 2025 | -40.98 Mn |
| Dec 31, 2025 | -40.98 Mn |
| Sep 30, 2025 | -32.81 Mn |
| Sep 30, 2025 | -32.81 Mn |
| Jun 30, 2025 | -37.76 Mn |
| Jun 30, 2025 | -37.76 Mn |
| Mar 31, 2025 | -36.48 Mn |
| Mar 31, 2025 | -36.48 Mn |
| Dec 31, 2024 | -37.48 Mn |
| Dec 31, 2024 | -37.48 Mn |
| Sep 30, 2024 | -12.58 Mn |
| Sep 30, 2024 | -12.58 Mn |
| Jun 30, 2024 | -54.19 Mn |
| Jun 30, 2024 | -54.19 Mn |
| Mar 31, 2024 | -54.99 Mn |
| Mar 31, 2024 | -54.99 Mn |
| Dec 31, 2023 | -33.08 Mn |
| Dec 31, 2023 | -33.08 Mn |